



Supplementary Fig. 2. EuroQoL-5 dimension visual analog scale (EQ-5D VAS) score. Data are from the full analysis set, with last observation carried forward. The full analysis set comprised of all randomized patients who received ≥ 1 dose of study drug. The full analysis set did not include patients who only received vedolizumab IV induction treatment and were not randomized into the maintenance phase. Data represent mean and standard deviation. VDZ, vedolizumab; SC, subcutaneous; IV, intravenous; PBO, placebo.



Supplementary Fig. 3. WPAI-UC scores by study visit. (A) WPAI-UC overall work productivity score. (B) WPAI-UC activity impairment score. Data are from the full analysis set, with last observation carried forward. The full analysis set comprised of all randomized patients who received ≥ 1 dose of study drug. The full analysis set did not include patients who only received vedolizumab IV induction treatment and were not randomized into the maintenance phase. Data represent mean and standard deviation. WPAI-UC, Work Productivity and Activity Impairment-ulcerative colitis; VDZ, vedolizumab; SC, subcutaneous; IV, intravenous; PBO, placebo.